GRPR-Targeted Radionuclide Theranostics Show Promising Diagnostic Value and Advancing Therapeutic Potential Across Multiple Cancers
Background
The gastrin-releasing peptide receptor (GRPR) is frequently overexpressed in several aggressive malignancies, including prostate cancer, estrogen receptor-positive breast cancer, lung cancer, and gastrointestinal stromal tumors (GISTs). This aberrant expression makes GRPR an attractive target for molecular imaging and targeted radionuclide therapy, offering a pathway for precision oncology. Current standard-of-care therapies often lack tumor specificity, leading to off-target toxicity and limited efficacy. Nuclear medicine's radiotheranostics approach aims to overcome these limitations by delivering diagnostic and therapeutic agents directly to cancer cells expressing specific receptors like GRPR.
Study Design
This comprehensive review systematically summarized recent advances in GRPR-targeted radioligands for both tumor imaging and radioligand therapy. The authors focused on the biological rationale, identified representative tracers, assessed their clinical utility, and discussed major limitations across various tumor types. The review analyzed progress in radioligand design, radionuclide selection, and theranostic concepts, synthesizing findings from numerous studies to provide a holistic view of GRPR-mediated oncologic applications in nuclear medicine.
Results
The review highlighted that GRPR-targeted imaging has demonstrated promising diagnostic value in prostate cancer, estrogen receptor-positive breast cancer, and selected gastrointestinal stromal tumors. It suggests that these imaging modalities may effectively complement existing diagnostic techniques. From a therapeutic standpoint, significant progress has been made, driven by the development of high-stability antagonists, metabolic protection strategies, and novel therapeutic radionuclides. This advancement is propelling GRPR-targeted radioligand therapy toward an improved therapeutic index and greater translational potential.
The development of high-stability antagonists and novel therapeutic radionuclides is driving GRPR-targeted radioligand therapy toward improved therapeutic index and greater translational potential.
Key Findings
- GRPR-targeted imaging shows promising diagnostic value in prostate cancer, estrogen receptor-positive breast cancer, and selected GISTs.
- Advances in radioligand design and radionuclide selection are improving GRPR-targeted theranostics.
- High-stability antagonists and metabolic protection strategies are enhancing the therapeutic index of GRPR-targeted radioligand therapy.
- GRPR-targeted approaches may complement existing imaging modalities for improved diagnostic accuracy.
Why It Matters
This review underscores a significant shift towards more precise and personalized oncology, offering a blueprint for future therapeutic strategies. GRPR-targeted theranostics could enable earlier, more accurate cancer diagnosis and deliver highly localized radiation therapy, potentially reducing systemic side effects and improving patient outcomes. For clinicians and biohackers, this highlights the growing potential of peptide-receptor targeting in cancer, suggesting that future protocols might integrate GRPR-specific agents for both diagnostic staging and therapeutic intervention. The emphasis on ligand engineering and individualized dosimetry indicates a move towards highly tailored treatment plans, optimizing efficacy while minimizing toxicity, though widespread clinical adoption requires further high-quality evidence.
grpr
oncology
theranostics
radioligand-therapy
prostate-cancer
breast-cancer